Edwards Lifesciences (NYSE:EW) Stock Gets Price Target Increase from Royal Bank Of Canada

Key Points

• RBC raised its price target on Edwards Lifesciences from $110 to $115 and maintained an “outperform” rating, implying about 15.5% upside from the cited share price.
• Edwards beat quarterly estimates, reporting EPS of $0.80 versus $0.74 expected and revenue of $1.72 billion versus $1.68 billion; sales grew year over year, and the company raised its full-year adjusted EPS outlook to $2.97–$3.05.
• Analyst sentiment is broadly positive, but increasing TAVR competition could pressure market share or pricing, and RBC cautioned that trial results may not substantially expand the market.

Edwards Lifesciences (NYSE:EW - Get Free Report) had its price objective raised by equities research analysts at Royal Bank Of Canada from $110.00 to $115.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the medical research company's stock. Royal Bank Of Canada's price target points to a potential upside of 15.48% from the stock's current price.

Several other brokerages have also recently issued reports on EW. Barclays raised their target price on shares of Edwards Lifesciences from $110.00 to $120.00 and gave the stock an "overweight" rating in a report on Thursday. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Saturday, October 31st. Argus boosted their target price on shares of Edwards Lifesciences from $105.00 to $115.00 and gave the company a "buy" rating in a research note on Friday, August 21st. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Friday, October 2nd. Finally, TD Cowen restated a "buy" rating on shares of Edwards Lifesciences in a research note on Tuesday, October 27th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, Edwards Lifesciences has an average rating of "Moderate Buy" and an average target price of $105.52.

Edwards Lifesciences Stock Up 0.2%

Shares of EW stock traded up $0.22 during mid-day trading on Thursday, hitting $99.59. The company's stock had a trading volume of 5,390,072 shares, compared to its average volume of 4,513,172. Edwards Lifesciences has a 52-week low of $74.66 and a 52-week high of $104.17. The business has a 50-day moving average price of $88.48 and a 200 day moving average price of $85.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock has a market cap of $57.34 billion, a price-to-earnings ratio of 57.21, a PEG ratio of 2.49 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The firm had revenue of $1.72 billion for the quarter, compared to the consensus estimate of $1.68 billion. During the same period in the prior year, the company posted $0.67 earnings per share. The company's quarterly revenue was up 10.5% on a year-over-year basis. Research analysts predict that Edwards Lifesciences will post 3.00 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares of the company's stock, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares of the company's stock, valued at $1,618,200.32. The trade was a 12.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,045 shares of company stock valued at $451,596 over the last 90 days. 0.31% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 1.2% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 10,615 shares of the medical research company's stock worth $916,000 after purchasing an additional 125 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its holdings in shares of Edwards Lifesciences by 1.8% in the third quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company's stock valued at $627,000 after purchasing an additional 132 shares during the last quarter. Calamos Wealth Management LLC lifted its position in Edwards Lifesciences by 6.1% during the third quarter. Calamos Wealth Management LLC now owns 2,438 shares of the medical research company's stock worth $210,000 after buying an additional 141 shares in the last quarter. Signaturefd LLC boosted its stake in Edwards Lifesciences by 1.4% during the third quarter. Signaturefd LLC now owns 10,034 shares of the medical research company's stock worth $866,000 after buying an additional 142 shares during the last quarter. Finally, NorthRock Partners LLC grew its holdings in Edwards Lifesciences by 1.0% in the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company's stock valued at $1,465,000 after buying an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80 and revenue of $1.72 billion, topping estimates. Sales grew 11.2% year over year, supported by 8.8% growth in TAVR and a 45.6% surge in transcatheter mitral and tricuspid therapies (TMTT). The company raised its full-year adjusted EPS outlook to $2.97–$3.05, reinforcing expectations for continued growth. Q3 earnings call highlights
• Positive Sentiment: New PROGRESS Trial results found TAVR performed better than active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes, fewer heart-failure hospitalizations and improved quality of life. The findings could support earlier use of the procedure; the company also expects procedure volumes to benefit from expanded Medicare reimbursement. PROGRESS Trial data
• Positive Sentiment: Several firms raised price targets after the results. Piper Sandler and BTIG set targets of $115, Baird upgraded EW to “outperform” with a $116 target, and JPMorgan raised its target to $120. These actions signal improved analyst expectations. JPMorgan price target change
• Negative Sentiment: Management cautioned that more competition is coming in TAVR, which could pressure market share or pricing. RBC also said the PROGRESS findings may not meaningfully expand the TAVR market, tempering expectations for the trial’s commercial impact. CEO comments on TAVR competition

About Edwards Lifesciences

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart's valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.